Capital Markets Day & Notice of trading update

Capital

hVIVO plc (AIM & Euronext: HVO), a fast growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it will be holding a Capital Markets Event at the Company's new state-of-the-art facility in Canary Wharf for analysts, institutional investors, and media on Wednesday 17 July 2024 at 10.00 am - 12.30 pm (BST). The Company also expects to announce a trading update for the six months ended 30 June 2024 on the same day.

The event will focus on the capabilities of the world's largest human challenge trial unit and how it will enhance and broaden hVIVO's services, as well as covering the Group's trading update. CEO Yamin 'Mo' Khan will chair the event that will include speakers from across the Group, as well as a fireside chat with a number of external speakers discussing the utility of human challenge trials. There will also be an opportunity for attendees to take part in Q&A sessions with the speakers and to tour the laboratory and challenge trial unit.

Analysts, institutional investors and media are welcome to attend the in-person event. Due to restrictions on numbers, it will not be possible for all interested parties to attend in-person, however, a live webcast will be available on the Company's website for retail investors and others to view the presentations here.

To register your interest for the event or webcast, please contact Walbrook PR on +44 20 7933 8780 or email hvivo@walbrookpr.com. A recording of the presentation will be made available on the Company's website after the event.